

Press release

Please fill in this form and return it to graduateschoolhealth@au.dk in Word format no later than three weeks prior to your defence.

Basic information

Name: Anders Schwartz Vittrup
+4526144873

Email: Anders.Schwartz.Vittrup@rm.dk Phone:

Department of: Clinical Medicine

Main supervisor: Kari Tanderup

Title of dissertation: Reporting of late morbidity after radiotherapy in locally advanced cervix cancer: severity and duration of physician and patient reported symptoms.

Date for defence: September 10th at (time of day): 3 PM Place: At Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, entrance C, level 1, Auditorium C114-101, DK-8200 Aarhus N.

Press release (Danish)

Senbivirkninger efter strålebehandling af livmoderhalskræft: sværhedsgrad og varighed af læge- samt patientrapporterede symptomer.

Lokalt avanceret livmoderhalskræft behandles med kemostrålebehandling efterfulgt af brachyterapi (intern strålebehandling). I løbet af de sidste årtier har behandlingen udviklet sig markant med bedre lokal kontrol og overlevelse til følge. Disse fremskridt har medført flere livmoderhalskræftoverlevende, som er i risiko for at opleve behandlingsrelaterede senbivirkninger i resten af deres liv. Rapportering af senbivirkninger efter strålebehandling er udfordret af det store antal kliniske endepunkter, som manifesterer sig forskelligt over tid i forskellige sværhedsgrader. Særlig er varigheden af symptomer en udfordring når senbivirkninger skal rapporteres. I et nyt ph.d.-projekt fra Aarhus Universitet, Health undersøges senbivirkninger efter kemostrålebehandling for lokalt avanceret livmoderhalskræft. Ph.D. projektet adresserer metodologiske udfordringer for rapportering af senbivirkninger efter strålebehandling. Der introduceres en ny metode til opgørelse af senbivirkninger der identificerer patienter med vedvarende symptomer (LAPERS) og LAPERS implementeres på patientrapporterede symptomer fra et stort prospektivt observationelt studie (EMBRACE). Endeligt gives der en oversigt over alvorlige senbivirkninger i EMBRACE-studiet. Projektet er gennemført af Anders Schwartz Vittrup, der forsvare det d. 10/09-2021.

Forsvaret af ph.d.-projektet er offentligt og finder sted den 10/09 kl. 15.00 på Aarhus Universitetshospital, Palle Juul-Jensens Boulevard 99, indgang C, etage 1, auditorium C114-101, DK-8200 Aarhus N. Titlen på projektet er: "Reporting of late morbidity after radiotherapy in locally advanced cervix cancer: severity and duration of physician and patient reported symptoms". Yderligere oplysninger: PhD studerende Anders Schwartz Vittrup, email: Anders.Schwartz.Vittrup@rm.dk, tlf. +45 26144873.

Bedømmelsesudvalg:

Professor, MD, Ingvild Vistad, Department of Clinical Sciences Haukeland Universitetssykehus, Laboratoriebygget, Bergen, Norge.

Professor, MD, PhD, Helle Pappot, Institut for Klinisk Medicin, Onkologisk klinik, Rigshospitalet, Danmark

Professor, MD, Lene Hjerrild Iversen, Institut for Klinisk Medicin, Mave- og Tarmkirurgi, Aarhus Universitetshospital, Danmark

Press release (English)

Reporting of late morbidity after radiotherapy in locally advanced cervix cancer: severity and duration of physician and patient reported symptoms.

Definitive treatment of locally advanced cervical cancer involves chemoradiation followed by brachytherapy (internal radiation). During the last decades, the treatment has evolved and impressive local control and survival rates have been achieved. The efficacy of the treatment has generated a growing number of cervical cancer survivors, at risk of living with treatment-related late morbidity potentially for the remainder of their lives. However, the reporting of late morbidity after radiotherapy is challenged by the vast number of endpoints with various manifestations patterns over time amounting to different grades of severity. In particular, the duration of morbidity remains a challenge when morbidity is reported. In a new PhD project from the faculty of Health, Aarhus University, the late side effects after definitive chemoradiotherapy of locally advanced cervical cancer are investigated. The project addresses methodological challenges for reporting late morbidity after radiotherapy. A new methodology (LAPERS) that identifies patients with persistent symptoms is introduced and implemented to patient-reported symptoms within the setting of a large prospective observational study (EMBRACE). Finally, an overview of physician-assessed severe morbidity in the EMBRACE study is provided. The project was carried out by Anders Schwartz Vittrup, who is defending his dissertation on September 10th 2021.

The defence is public and takes place on September 10th at Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, entrance C, level 1, Auditorium C114-101, DK-8200 Aarhus N. The title of the project is: "Reporting of late morbidity after radiotherapy in locally advanced cervix cancer: severity and duration of physician and patient reported symptoms". For more information, please contact PhD student Anders Schwartz Vittrup, email: Anders.Schwartz.Vittrup@rm.dk, Phone +45 26144873.

Assessment committee:

Ingvild Vistad, Professor, MD

Department of Clinical Sciences Haukeland universitetssykehus, Laboratoriebygget University of Bergen, Norway

Helle Pappot, Professor, MD, PhD

Department of Clinical Medicine - Department of Oncology, University of Copenhagen - Rigshospitalet, Denmark

Lene Hjerrild Iversen, Professor, MD (chairman and moderator of the defence)

Department of Clinical Medicine - Department of Surgery, Aarhus University Hospital, Denmark

Permission

By sending in this form:

- I hereby grant permission to publish the above Danish and English press releases.
- I confirm that I have been informed that any applicable inventions shall be treated confidentially and shall under no circumstances whatsoever be published, presented or mentioned prior to submission of a patent application, and that I have an obligation to inform my head of department and the university's Patents Committee if I believe I have made an invention in connection with my work. I also confirm that I am not aware that publication violates any other possible holders of a copyright.